Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson’s disease model

ITAKURA, Masanori; Kohda, Tomoko; Kubo, Takeya; Semi, Yuko; Azuma, Yasu-Taka; Nakajima, Hidemitsu; Kozaki, Shunji; Takeuchi, Tadayoshi

doi:10.1016/j.bbrc.2014.03.146

Article (Scientific journals)

Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson’s disease model

ITAKURA, Masanori; Kohda, Tomoko; Kubo, Takeya et al.

2014 • In Biochemical and Biophysical Research Communications, 447 (2), p. 311-314

Editorial Reviewed verified by ORBi

Permalink
https://hdl.handle.net/10993/58203

DOI
10.1016/j.bbrc.2014.03.146

PubMed
24713302

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

pdf.sciencedirectassets.com 2019_7_21 18 06 51.pdf

Author postprint (1.19 MB)

Download

All documents in ORBilu are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Recent reports indicate that interruption of acetylcholine release by intrastriatal injection of botulinum neurotoxin type A (BoNT/A) in a rat Parkinson’s disease model reduces pathogenic behavior without adverse side effects such as memory dysfunction. Current knowledge suggests that BoNT/A subtype 1 (BoNT/A1) and BoNT/A subtype 2 (BoNT/A2) exert different effects. In the present study, we compared the effects of BoNT/A1 and BoNT/A2 on rotation behavior and in vivo cleavage of presynaptic protein SNAP-25 in a rat unilateral 6-hydroxydopamine-induced Parkinson’s disease model. BoNT/A2 more effectively reduced pathogenic behavior by efficiently cleaving SNAP-25 in the striatum compared with that of BoNT/A1. Our results suggest that BoNT/A2 has greater clinical therapeutic value for treating subjects with Parkinson’s disease compared to that of BoNT/A1.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

ITAKURA, Masanori ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Neuroinflammation Group

Kohda, Tomoko

Kubo, Takeya

Semi, Yuko

Azuma, Yasu-Taka

Nakajima, Hidemitsu

Kozaki, Shunji

Takeuchi, Tadayoshi

External co-authors :

yes

Language :

English

Title :

Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson’s disease model

Publication date :

2014

Journal title :

Biochemical and Biophysical Research Communications

ISSN :

0006-291X

eISSN :

1090-2104

Publisher :

Elsevier, Atlanta, Us ca

Volume :

447

Issue :

Pages :

311-314

Peer reviewed :

Editorial Reviewed verified by ORBi

Additional URL :

https://app.readcube.com/library/a9ec3f18-47dd-4e50-bc89-1e8528daa3d7/item/b6b5c87c-e8af-432d-80c9-fe8899b1d776

Available on ORBilu :

since 29 November 2023

Statistics

Number of views

53 (1 by Unilu)

Number of downloads

45 (0 by Unilu)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

F. Antonucci, C. Rossi, L. Gianfranceschi, O. Rossetto, and M. Caleo Long-distance retrograde effects of botulinum neurotoxin A J. Neurosci. 28 2008 3689 3696
A. Hawlitschka, V. Antipova, O. Schmitt, M. Witt, R. Benecke, E. Mix, and A. Wree Intracerebrally applied botulinum neurotoxin in experimental neuroscience Curr. Pharm. Biotechnol. 14 2013 124 130
S. Knuepfer, and K.P. Juenemann Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice Ther. Adv. Urol. 6 2014 34 42
O. Rossetto, A. Megighian, M. Scorzeto, and C. Montecucco Botulinum neurotoxins Toxicon 67 2013 31 36
J. Jankovic Botulinum toxin in clinical practice J. Neurol. Neurosurg. Psychiatry 75 2004 951 957
R.C. Whitemarsh, W.H. Tepp, M. Bradshaw, G. Lin, C.L. Pier, J.M. Scherf, E.A. Johnson, and S. Pellett Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro Infect. Immun. 81 2013 3894 3902
J.W. Arndt, M.J. Jacobson, E.E. Abola, C.M. Forsyth, W.H. Tepp, J.D. Marks, E.A. Johnson, and R.C. Stevens A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4 J. Mol. Biol. 362 2006 733 742
J.S. Henkel, M. Jacobson, W. Tepp, C. Pier, E.A. Johnson, and J.T. Barbieri Catalytic properties of botulinum neurotoxin subtypes A3 and A4 Biochemistry 48 2009 2522 2528
M. Day, Z. Wang, J. Ding, X. An, C.A. Ingham, A.F. Shering, D. Wokosin, E. Ilijic, Z. Sun, A.R. Sampson, E. Mugnaini, A.Y. Deutch, S.R. Sesack, G.W. Arbuthnott, and D.J. Surmeier Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models Nat. Neurosci. 9 2006 251 259
J.A. Obeso, M.C. Rodriguez-Oroz, B. Benitez-Temino, F.J. Blesa, J. Guridi, C. Marin, and M. Rodriguez Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease Mov. Disord. 23 Suppl 3 2008 S548 S559
A. Wree, E. Mix, A. Hawlitschka, V. Antipova, M. Witt, O. Schmitt, and R. Benecke Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease Neurobiol. Dis. 41 2011 291 298
V. Antipova, A. Hawlitschka, E. Mix, O. Schmitt, D. Drager, R. Benecke, and A. Wree Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease J. Neurosci. Res. 91 2013 838 847
C. Holzmann, D. Drager, E. Mix, A. Hawlitschka, V. Antipova, R. Benecke, and A. Wree Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats Behav. Brain Res. 234 2012 107 116
K. Kato, N. Akaike, T. Kohda, Y. Torii, Y. Goto, T. Harakawa, A. Ginnaga, R. Kaji, and S. Kozaki Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy Toxicon 74 2013 109 115
S. Kozaki, S. Sakaguchi, and G. Sakaguchi Purification and some properties of progenitor toxins of Clostridium botulinum type B Infect. Immun. 10 1974 750 756
S. Sugii, and G. Sakaguchi Molecular construction of Clostridium botulinum type A toxins Infect. Immun. 12 1975 1262 1270
M. Aoi, I. Date, S. Tomita, and T. Ohmoto The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages Neurosci. Res. 36 2000 319 325
G. Paxinos, C. Watson, M. Pennisi, and A. Topple Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight J. Neurosci. Methods 13 1985 139 143
Y. Torii, N. Akaike, T. Harakawa, K. Kato, N. Sugimoto, Y. Goto, S. Nakahira, T. Kohda, S. Kozaki, R. Kaji, and A. Ginnaga Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats J. Pharmacol. Sci. 117 2011 275 285
Y. Torii, N. Kiyota, N. Sugimoto, Y. Mori, Y. Goto, T. Harakawa, S. Nakahira, R. Kaji, S. Kozaki, and A. Ginnaga Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test Toxicon 57 2011 93 99
C.L. Pier, C. Chen, W.H. Tepp, G. Lin, K.D. Janda, J.T. Barbieri, S. Pellett, and E.A. Johnson Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1 FEBS Lett. 585 2011 199 206
Y. Torii, Y. Goto, S. Nakahira, S. Kozaki, and A. Ginnaga Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies Toxicon 77 2014 114 120